ABOUT HOTH THERAPEUTICS

focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.

ABOUT HOTH THERAPEUTICS

BioLexa PlatformTM

Hoth Therapeutics is a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.

Hoth owns the exclusive rights to develop the BioLexa PlatformTM for all indications in humans. The BioLexa PlatformTM is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa PlatformTM combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.

We intend to explore the use of the BioLexa PlatformTM for the treatment of atopic dermatitis, or eczema.

We also intend to explore the use of the BioLexa PlatformTM in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. We believe that the BioLexa PlatformTM’s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.

Finally, we intend to explore the use of the BioLexa PlatformTM in connection with diabetic foot ulcers. We believe that the BioLexa PlatformTM‘s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus.

Genetic Marker License

Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.

INVESTOR RELATIONS

Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.